BACKGROUND: The carbohydrate sialyl Lewis X (sLeX) is expressed on leukocytes and carcinoma cells and binds to selectins during inflammatory processes and early metastasis. Synthesis of sLeX depends on activity of enzymes, including α(1,3/1,4) fucosyltransferase (FucT-III). Tumor necrosis factor-α (TNF-α) up-regulates FucT-III, resulting in increased sLeX in the airways of patients with respiratory disease; however, the mechanisms that regulate sLeX in the inflammatory tumor microenvironment are not well understood. METHODS: The authors stably transfected human lung carcinoma cell lines with the FucT-III gene and exposed them to TNF-α to investigate its role in regulation of sLeX expression and selectin-binding ability using semiquantitative real-time polymerase chain reaction and flow cytometry. Cytokine expression was examined in transfected cells using chemiluminescent arrays and enzyme-linked immunosorbent assays, and invasion was studied using Matrigel assays and alterations in morphology. Human lung tissue arrays were analyzed for immunohistochemical detection of sLeX and neutrophils. RESULTS: Stimulation of FucT-III-transfected cells with recombinant human (rh) TNF-α up-regulated sLeX expression and increased E-selectin binding. Transfected cells secreted high levels of interleukin 8, growth-regulated oncogene-α, and mast cell proteinase-1. Cells exposed to rhTNF-α, neutrophil-conditioned media, and cultures with a 5:1 ratio of neutrophils to cancer cells had significantly increased sLeX expression and invasiveness and underwent nonadherent morphologic changes. In lung carcinomas, but not in normal lung tissues, 71% of tumors were highly positive for sLeX expression in areas of increased neutrophil infiltration. CONCLUSIONS: The current results indicated that neutrophils may be recruited to areas of FucT-III activity and sLeX expression in lung carcinomas to enhance the invasive and metastatic potential of lung cancer cells.
BACKGROUND: The carbohydrate sialyl Lewis X (sLeX) is expressed on leukocytes and carcinoma cells and binds to selectins during inflammatory processes and early metastasis. Synthesis of sLeX depends on activity of enzymes, including α(1,3/1,4) fucosyltransferase (FucT-III). Tumor necrosis factor-α (TNF-α) up-regulates FucT-III, resulting in increased sLeX in the airways of patients with respiratory disease; however, the mechanisms that regulate sLeX in the inflammatory tumor microenvironment are not well understood. METHODS: The authors stably transfected humanlung carcinoma cell lines with the FucT-III gene and exposed them to TNF-α to investigate its role in regulation of sLeX expression and selectin-binding ability using semiquantitative real-time polymerase chain reaction and flow cytometry. Cytokine expression was examined in transfected cells using chemiluminescent arrays and enzyme-linked immunosorbent assays, and invasion was studied using Matrigel assays and alterations in morphology. Human lung tissue arrays were analyzed for immunohistochemical detection of sLeX and neutrophils. RESULTS: Stimulation of FucT-III-transfected cells with recombinant human (rh) TNF-α up-regulated sLeX expression and increased E-selectin binding. Transfected cells secreted high levels of interleukin 8, growth-regulated oncogene-α, and mast cell proteinase-1. Cells exposed to rhTNF-α, neutrophil-conditioned media, and cultures with a 5:1 ratio of neutrophils to cancer cells had significantly increased sLeX expression and invasiveness and underwent nonadherent morphologic changes. In lung carcinomas, but not in normal lung tissues, 71% of tumors were highly positive for sLeX expression in areas of increased neutrophil infiltration. CONCLUSIONS: The current results indicated that neutrophils may be recruited to areas of FucT-III activity and sLeX expression in lung carcinomas to enhance the invasive and metastatic potential of lung cancer cells.
Authors: S Kuninaka; T Yano; H Yokoyama; Y Fukuyama; Y Terazaki; T Uehara; T Kanematsu; H Asoh; Y Ichinose Journal: Cytokine Date: 2000-01 Impact factor: 3.861
Authors: A Togayachi; T Kudo; Y Ikehara; H Iwasaki; S Nishihara; T Andoh; M Higashiyama; K Kodama; S Nakamori; H Narimatsu Journal: Int J Cancer Date: 1999-09-24 Impact factor: 7.396
Authors: J D Schwartz; S Monea; S G Marcus; S Patel; K Eng; A C Galloway; P Mignatti; P Shamamian Journal: J Surg Res Date: 1998-04 Impact factor: 2.192
Authors: Zvi G Fridlender; Jing Sun; Samuel Kim; Veena Kapoor; Guanjun Cheng; Leona Ling; G Scott Worthen; Steven M Albelda Journal: Cancer Cell Date: 2009-09-08 Impact factor: 31.743
Authors: Catherine A St Hill; Mariya Farooqui; Gregory Mitcheltree; H Evin Gulbahce; Jose Jessurun; Qing Cao; Bruce Walcheck Journal: BMC Cancer Date: 2009-03-06 Impact factor: 4.430
Authors: M Matossian; C Vangelderen; P Papagerakis; L Zheng; G T Wolf; S Papagerakis Journal: Int J Immunopathol Pharmacol Date: 2014 Oct-Dec Impact factor: 3.219
Authors: María G Ramírez-Ledesma; Yordan J Romero-Contreras; Mayra C Rodríguez; Ruth Reyes-Cortes; Patricia Cuéllar-Mata; Eva E Avila Journal: Parasitol Res Date: 2022-03-08 Impact factor: 2.289
Authors: Catarina Gomes; Hugo Osório; Marta Teixeira Pinto; Diana Campos; Maria José Oliveira; Celso A Reis Journal: PLoS One Date: 2013-06-14 Impact factor: 3.240
Authors: Pedro Enrique Guerrero; Laura Miró; Bin S Wong; Anna Massaguer; Neus Martínez-Bosch; Rafael de Llorens; Pilar Navarro; Konstantinos Konstantopoulos; Esther Llop; Rosa Peracaula Journal: Int J Mol Sci Date: 2020-08-28 Impact factor: 5.923